FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091888711> ?p ?o ?g. }

• W2091888711 endingPage "186" @default.
• W2091888711 startingPage "165" @default.
• W2091888711 abstract "CNS Drug ReviewsVolume 4, Issue 2 p. 165-186 Free Access The Preclinical and Therapeutic Activity of the Novel Anticonvulsant Topiramate Roberto Michelucci, Corresponding Author Roberto Michelucci Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalyDr. R. Michelucci, Department of Neurology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy. Fax: 51-622-5369.Search for more papers by this authorDaniela Passarelli, Daniela Passarelli Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalySearch for more papers by this authorPatrizia Riguzzi, Patrizia Riguzzi Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalySearch for more papers by this authorLilia Volpi, Lilia Volpi Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalySearch for more papers by this authorC. Alberto Tassinari, C. Alberto Tassinari Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalySearch for more papers by this author Roberto Michelucci, Corresponding Author Roberto Michelucci Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalyDr. R. Michelucci, Department of Neurology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy. Fax: 51-622-5369.Search for more papers by this authorDaniela Passarelli, Daniela Passarelli Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalySearch for more papers by this authorPatrizia Riguzzi, Patrizia Riguzzi Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalySearch for more papers by this authorLilia Volpi, Lilia Volpi Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalySearch for more papers by this authorC. Alberto Tassinari, C. Alberto Tassinari Department of Neurological Sciences, University of Bologna, Bellaria Hospital, Bologna, ItalySearch for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3458.1998.tb00062.xCitations: 4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Abou Khalil B, the YOL Topiramate Study Group. Topiramate therapy in the long-term management of epilepsy. Epilepsia 1997; 38(Suppl 3): 60. 2 Avoli M, Kawasaki H, Zona C. Effects induced by topiramate on sodium electrogenesis in mammalian central neurons. Epilepsia 1996; 37(Suppl 4): 51– 52. 3 Bauer G, Crawford P, Ganger R, the YOL-E Study Group. Open-label, long-term topiramate therapy for epilepsy. Epilepsia 1997; 38(Suppl 3): 58– 59. 4 Ben Menachem E. Potential antiepileptic drugs: Topiramate. In: RH Levy, RH Mattson, BS Meldrum, eds. Antiepileptic drugs, fourth edition. New York : Raven Press, 1995: 1063– 1070. 5 Ben Menachem E. Long-term follow-up of patients treated with topiramate for partial seizures. Epilepsia 1995; 36(Suppl 3): S152. 6 Ben Menachem E. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience. Epilepsia 1997; 38(Suppl 1): S28– S30. 7 Ben Menachem E. Topiramate. Current status and therapeutic potential. Exp Opin Invest Drugs 1997; 6: 1085– 1094. 8 Ben Menachem E, Abrahamsson H. Gastroscopic evaluation of patients with complex partial seizures treated with topiramate. Epilepsia 1994; 35(Suppl 8): 116. 9 Ben Menachem E, the Topiramate YTC-E Study Group. A double-blind trial of topiramate in patients with generalized tonic-clonic seizures of non-focal origin. Epilepsia 1997; 38(Suppl 3): 60. 10 Ben Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37: 539– 543. 11 Bill P, Bhigjee A, Eastman R, Carr P. Long term open label study of topiramate. Epilepsia 1997; 38(Suppl 3): 63. 12 Biton V, Montouris GD, the YTC Study Team. Topiramate double-blind trial in patients with generalized tonic-clonic seizures of non-focal origin. Epilepsia 1997; 38(Suppl 3): 59– 60. 13 Bourgeois BFD. Drug-interaction profile of topiramate. Epilepsia 1996; 37(Suppl 2): S14– S17. 14 Brodie MJ, Biton V, Montouris GD, Shu-Chen W. Topiramate therapy in patients with generalized tonic-clonic seizures without focal onset: Long-term outcome. Epilepsia 1998; 39(Suppl 2): 2. 15 Brown SD. Wolf HH, Swinyard EA, Twyman RE, White HS. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993; 34(Suppl 2): 122– 123. 16 Buben JA, Ferraiolo BL. Evaluation of the tissue distribution of total radioactivity and topiramate in pregnant and nongravid female Sprague-Dawley rats following a single oral dose of 20 mg kg [14C]topi-ramate. Data on file at RWJPRI (June 1991). 17 Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Res 1997; 27: 29– 32. 18 Canger R, Avanzini G, Tartara A, et al. Long-term efficacy and tolerability of topiramate add-on therapy. Interim. analysis after four years of treatment. Epilepsia 1997; 38(Suppl 3): 59. 19 Chadwick DW. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia 1997; 38(Suppl 1): S59– S62. 20 Clark PO, Glauser T, Strawsburg R. Pilot study of TPM in children with infantile spasms. Epilepsia 1997; 38(Suppl 8): 96– 97. 21 Coulter DA, Sombati S, De Lorenzo RJ. Selective effects of TPM on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993; 34(Suppl 2): 123. 22 Davis CB, Schupsky JJ, Shank RP, et al. Anticonvulsant activity of two metabolites (RWJ-36638-000 and RWJ-38213-000) and a putative metabolite (RWJ-34826-000) of topiramate in mice. Data on file at RWJPRI (June 1992). 23 De Luca RB. Review summary of toxicological study KW-6485 (topiramate). Repeated oral administration toxicity study for 13 weeks in rats. Data on file at RWJPRI (March 1994). 24 De Luca RB, Costa JF. Acute intraperitoneal toxicity study of McN-4853 in Crl:COBS (WI) BR rats. Data on file at RWJPRI (July 1985). 25 De Luca RB, Costa JF, Cameron AM. Acute intraperitoneal toxicity study of McN-4853 in Crl:COBS CD-I (ICR) BR mice. Data on file at RWJPRI (February 1986). 26 Doose DR, Scott VV, Margul BL, et al. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia 1988; 29: 662. 27 Doose DR, Gisclon LG, Stellar SM, Riffits JM, Hills JF. The effect of food on the bioavailability of topiramate from 100 and 400-mg tablets in healthy male subjects. Epilepsia 1992; 33(Suppl 3): 105. 28 Doose DR, Walker SA, Gisclon LG. Evaluation of the relative bioavailability of topiramate from a 100-mg tablet with reference to a solution dosage form and the effect of food on the bioavailability of topi-ramate from the tablet dosage form. Data on file at RWJPRI (September 1993). 29 Doose DR, Walker SA, Venkataramanan R, et al. Topiramate pharmacokinetics in subjects with liver impairment. Pharm Res 1994; 11(Suppl): 446. 30 Doose DR, Walker SA, Pledger G, et al. Evaluation of phenobarbital and primidone phenobarbital (pri-midone's active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multicenter, double-blind, placebo-controlled trials in outpatients with partial seizures. Epilepsia 1995; 36(Suppl 3): 158. 31 Doose DR, Walker SA, Gisclon LG, Nayak RK. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996; 36: 884– 891. 32 Easterling DE, Zakzewski T, Moyer MD, et al. Plasma pharmacokinetics of topiramate, a new anticon-vulsant in humans. Epilepsia 1988; 29: 662. 33 Edmonds HL, Jiang YD, Zhang PY, Shank RP. Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. Life Sci 1996; 59: 127– 131. 34 Edwards K, Norton J, Potter D. Assessment of efficacy and tolerability of topiramate in slow versus rapid titration. Epilepsia 1997; 38(Suppl 3): 59. 35 Elferink AJA, Van Zwieten-Boot BJ. Analysis based on number needed to treat shows differences between drugs studied. BMJ 1997; 314: 603. 36 Elterman R, Glauser TA, Ritter FJ, et al. A double-blind trial of topiramate in partial seizures in children. Epilepsia 1997; 38(Suppl 3): 131. 37 Evans CR, Streeter AJ, Holland ML, et al. Effects of daily oral administration of topiramate (10, 55, or 300 mg kg d) to male and female Crl:COBS (WI) BR rats for nine months on the activity of hepatic microsomal drug metabolizing enzymes. Data on file at RWJPRI (March 1994). 38 Faught E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience. Epilepsia 1997; 38(Suppl 1): S24– S27. 39 Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996; 46: 1684– 1690. 40 Fincham RW, Schottelius DD. Long term therapy with topiramate in patients with partial seizures. Epi-lepsia 1995; 36(Suppl 4): 56. 41 French JA, Bourgeois BFD, Dreifuss FE, et al. An open-label multicenter study of topiramate inpatients with the Lennox Gastaut syndrome. Neurology 1995; 45(Suppl 4): A250. 42 Gardocki JF, Labinski LS, Brown GL, Maryanoff BE. Anticonvulsant activity of McN-4853 (M) 2,3:4,5-bis-O-(L-methylethylidene)-b-D-fructopyranose sulfamate in mice and rats. Epilepsia 1986; 27: 648– 649. 43 Gisclon LG, Curtin CR. The pharmacokinetics of topiramate in subjects with end-stage renal disease undergoing hemodialysis. 95th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 1994: 196. 44 Gisclon LG, Riffits JM, Sica DA, Gehr T, Ruddley J. The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function. Pharm Res 1993; 10(Suppl): S397. 45 Gisclon LG, Curtin CR, Kramer LD, Sachdeo RC, Levy RH. The steady-state (SS) pharmacokinetics of phenytoin (Dilantin) and of topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia 1994; 35(Suppl 8): 54. 46 Glauser TA. Topiramate. Sem Ped Neurol 1997; 4: 34– 42. 47 Glauser TA, Sachdeo RC, Ritter FJ, et al. A double-blind trial of topiramate in Lennox-Gastaut syndrome (LGS). Epilepsia 1997; 38(Suppl 3): 131. 48 Glauser TA, Wyllie E, Elterman R, Shu-Chen W. Topiramate initiated as add-on therapy in children with partial onset seizures: Long-term findings. Epilepsia 1998; 39(Suppl 2): 92. 49 Guberman A, Bruni J, Schmeiderman J, Couture M. Canadian long-term experience with topiramate. Epilepsia 1996; 37(Suppl 4): 67. 50 Guerreiro C, Campos CJR, Campos MFCR, et al. Long-term efficacy and safety of topiramate in partial epilepsy. Epilepsia 1997; 38(Suppl 3): 70. 51 Herranz JL, Arteaga R, de las Cuevas I. Topiramate in the treatment of children with Lennox-Gastaut syndrome. Epilepsia 1997; 38(Suppl 3): 37. 52 Hosford DA, Wang Y. Utility of the lethargic (lh lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997; 38: 408– 414. 53 Johannessen SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia 1997; 38(Suppl 1): S18– S23. 54 Khan A, Faught E, Kuzniecky R, Gilliam F, Laich E. Acute psychotic symptoms induced by topiramate. Epilepsia 1997; 38(Suppl 8): 97. 55 Kimishina K, Wang Y, Tanabe K. Anticonvulsant activities and properties of topiramate. Jpn J Pharma-col 1993; 58(Suppl 1): 211. 56 Krayer JH, Kenel MF. McN-4853: Teratology study in the mouse. Data on file at RWJPRI (February 1986). 57 Kugler SL, Sachdeo R, Wenger E, et al. Efficacy of topiramate in Lennox-Gastaut syndrome. Ann Neurol 1996; 40: 303. 58 Langtry HD, Gillis JC, Davis R. Topiramate: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54: 752– 773. 59 Liao S, Palmer M. Digoxin and topiramate drug interaction study in male volunteers. Pharm Res 1993; 10(Suppl): S405. 60 Luef G, Bauer G. Topiramate in drug-resistant partial and generalized epilepsies. Epilepsia 1996; 37(Suppl 4): 69. 61 Maddox JR, De Luca RB. Acute oral toxicity study of McN-4853 in Crl:COBS CD-1 (ICR) BR mice. Data on file at RWJPRI (February 1986). 62 Maddox JR, De Luca RB. Acute oral toxicity study of McN-4853 in Crl:COBS (WI) BR rats. Data on file at RWJPRI (February 1986). 63 Manreza MLG, Guerreiro M, Ferreira VE, et al. Long-term efficacy and safety of topiramate in Lennox-Gastaut syndrome. Epilepsia 1997; 38(Suppl 3): 98. 64 Marson AG, Kadir ZA, Chadwick DW. The new antiepileptic drugs: A systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169– 1174. 65 Michelucci R, Passarelli D, Tassinari CA. Topiramate in the treatment of refractory epilepsy: A two-year long-term follow-up. Epilepsia 1996; 37(Suppl 4): 70– 71. 66 Michelucci R, Passarelli D, Riguzzi P, Volpi L, Tassinari CA. Long-term follow-up of TPM in refractory partial seizures. Epilepsia 1998; 39(Suppl 2): 67. 67 Mosher AH. Effect of topiramate on gastric morphology and serum gastrin in the rat and mouse: Summary of three chronic topiramate studies in rodents. Data on file at RWJPRI (March 1990). 68 Nakamura F, Hiyoshi T, Kudo T, et al. Anticonvulsant effect of topiramate (2,3:4,5-bis-O-[1-methyl-ethylidene]b-D-fructopyranose sulfate) on amygdaloid kindled seizures in the cat. Jpn J Psychiatry Neurol 1993; 47: 394– 395. 69 Nakamura J, Tamura S, Kanda T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA 2 mice. Eur J Pharmacol 1994; 254: 83– 89. 70 Nayak RK, Gisclon LG, Curtin CA, Benet LZ. Estimation of the absolute bioavailability of topiramate in humans, without intravenous data. J Clin Pharmacol 1994; 34: 1029. 71 Norton J, Potter D, Edwards K. Sustained weight loss associated with topiramate. Epilepsia 1997; 38(Suppl 3): 60. 72 Penovich PE, Schoreder M, Gates JR, Moriarty GL. Clinical experience with topiramate: Correlation of serum levels with efficacy and adverse events. Epilepsia 1997; 38(Suppl 8): 181. 73 Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epi-lepsia 1996; 37(Suppl 2): S8– S13. 74 Polizzi G, O'Donoghue MF, Duncan JS, Shorvon SD, Sander JWS. A prospective, pragmatic, open label study of efficacy and tolerability of topiramate in the treatment of severe epilepsies. Epilepsia 1997; 38(Suppl 3): 67. 75 Pritchard JF. Binding of McN-4853 to plasma and erythrocytes of rat, mouse, rabbit, dog, monkey, and human to human serum. Data on file at RWJPRI (May 1985). 76 Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, 1000-mg daily dosages. Neurology 1996; 46: 1678– 1683. 77 Proest G, Steinhoff S, Ried S, et al. Open label add-on trial with topiramate (Topamax) in patients with partial epilepsy. Epilepsia 1995; 36(Suppl 3): S151. 78 Reife RA, Pledger GW. Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997; 38(Suppl 1): S31– S33. 79 Renzi NL, Dvorchik BH. Evaluation of the absorption, excretion, and biotransformation of McN-4853 following a single oral solution dose of [14C]McN-4853 (90 mg kg) to Sprague-Dawley rats. Data on file at RWJPRI (February 1994). 80 Ritter FJ, Glauser TA, Sachdeo RC, Shu-Chen W. Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia 1998; 39(Suppl 2): 2– 3. 81 Rosenfeld WE, Doose DR, Walker SA. The steady-state pharmacokinetics of topiramate as adjunctive therapy in pediatric subjects with epilepsy. Epilepsia 1995; 36(Suppl 3): 158. 82 Rosenfeld W, Abou-Khalil B, Morrell M, Reife R, Pledger G, Hayden R. Double-blind placebo-controlled trial of topiramate adjunctive therapy for partial-onset epilepsy. Epilepsia 1996; 37(Suppl 4): 5. 83 Rosenfeld WE, Doose DR, Walker SA, Nayack RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38: 317– 323. 84 Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topi-ramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997; 38: 324– 333. 85 Rosenfeld WE, Sachdeo RC, Faught RE, Privitera M. Long-term experience with topiramate as adjunc-tive therapy and as monotherapy in patients with partial onset seizures: Retrospective survey of open-label treatment. Epilepsia 1997; 38(Suppl 1): S34– S36. 86 Rosenfeld WE, Schaefer PA, Pace K. Weight loss patterns with topiramate therapy. Epilepsia 1997; 38(Suppl 3): 58. 87 Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacoki-netics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996; 37: 774– 780. 88 Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997; 38: 294– 300. 89 Sander JWA. Practical aspects of the use of topiramate in patients with epilepsy. Epilepsia 1997; 38(Suppl 1): S56– S58. 90 Schardein JL. Chemically induced birth defects, 2nd ed. New York : Marcel Dekker, Inc. 1993; 84– 85. 91 Severt L, Coulter DA, Sombati S, De Lorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia 1995; 36(Suppl 4): 38. 92 Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: Preclinical evaluation of a structurally novel an-ticonvulsant. Epilepsia 1994: 35: 450– 460. 93 Sharief M, Viteri C, Ben Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996; 25: 217– 224. 94 Shorvon S. Safety of topiramate: Adverse events and relationships to dosing. Epilepsia 1996; 37(Suppl 2): S18– S22. 95 Shorvon S, Stefan H. Overview of the safety of newer antiepileptic drugs. Epilepsia 1997; 38(Suppl 1): S45– S51. 96 Smith RB, Cameron AM, Williams ER. Twelve-month oral toxicity study of McN-4853 (topiramate) in beagle dogs. Data on file at RWJPRI (November 1988). 97 Smith RB, Kircher CH, Williams ER. Twelve-month toxicity study of topiramate administered as a dietary admixture to Crl:COBS (WI) BR rats. Data on file at RWJPRI (March 1989). 98 Streeter AJ, Takacs AR, Ferraiolo BL, et al. Evaluation of the bioavailability and pharmacokinetics of topiramate in female Sprague-Dawley rats administered a single intravenous (15 mg kg) or oral (30 mg kg) dose. Data on file at RWJPRI (November 1992). 99 Streeter AJ, Desai DM, Takacs AR, et al. Evaluation of the pharmacokinetics of topiramate in female New Zealand white rabbits administered single (60 mg kg) or multiple (60 mg kg day for 14 days) oral doses. Data on file at RWJPRI (July 1993). 100 Streeter AJ, Stable PL, Holland ML, Pritchard JF, Takacs AR. Pharmacokinetics and bioavailability of topiramate in the beagle dog. Drug Metab Dispos 1995; 23: 90– 93. 101 Tartara A, Sartori I, Manni R, et al. Efficacy and safety of topiramate in refractory epilepsy: A long term prospective trial. Ital J Neurol Sci 1996; 17: 429– 432. 102 Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996; 37: 763– 768. 103 Vaught JL. Review summary of the evaluation of topiramate as a neuroprotectant, seizure prophylactic and anticonvulsant in a rat model of complete global ischemia. Data on file at RWJPRI (August 1991). 104 Wasserstein A, Reife R, Rak I. Topiramate and nephrolithiasis. Epilepsia 1995; 36(Suppl 3): S153. 105 Wasserstein A, Reife R, Rak I. Mechanistic basis for topiramate-associated nephrolithiasis: examination of urinary and serum constituents. Epilepsia 1995; 36(Suppl 3): S153. 106 Wauquier A, Zhou S. Topiramate: A potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996; 24: 73– 77. 107 White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997; 38(Suppl 1): S9– S17. 108 White HS, Skradski S. The novel antiepileptic drug topiramate (TPM) blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 1997; 38(Suppl 3): 144– 145. 109 White HS, Brown SD, Wolf HH, et al. The anticonvulsant topiramate potentiates GABA evoked chloride current in mouse cortical neurons. Epilepsia 1994; 35(Suppl 8): 67. 110 White HS, Brown D, Skeen GA, Wolf HH, Twyman RE. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked currents. Epilepsia 1995; 36(Suppl 3): 39– 40. 111 White HS, Woodhead JH, Franklin MR, Swinyard EA, Wolf HH. General principles: experimental selection, quantification and evaluation of antiepileptic drugs. In: RH Levy, RH Mattson, BS Meldrum, eds. Antiepileptic drugs, fourth edition. New York : Raven Press 1995; 99– 110. 112 White HS, Woodhead JH, Wolf HH. Effect of topiramate (TPM) on pentylenetetrazol (PTZ) seizure threshold. Epilepsia 1996; 37(Suppl 5): 26. 113 Wu WN, Masucci JA, Takacs AR, et al. Isolation and identification of topiramate RWJ-17021-114 me-tabolites from Sprague-Dawley rats and beagle dogs. Data on file at RWJPRI (September 1993). 114 Wu WN, Heebner JB, Streeter AJ, et al. Evaluation of the absorption, excretion, pharmacokinetics, and metabolism of the anticonvulsant topiramate in healthy men. Pharm Res 1994; 11(Suppl): S-336. 115 Yuschak MM, De Luca RB. Acute oral toxicity study of McN-4853 in beagle dogs. Data on file at RWJPRI (November 1985). 116 Zappacosta PS, Evans CR, Renzi NL, et al. Evaluation of the absorption, excretion, and biotransformation of McN-4853 in male and female beagle dogs following a single, 40 mg kg, oral solution dose of [14C]McN-4853. Data on file at RWJPRI (February 1994). 117 Zellers JE, Krayer JH. Review summary of reproductive and developmental toxicity study of KW-6485 (topiramate), teratogenicity study in rats. Data on file at RWJPRI (May 1994). 118 Zellers JE, Krayer JH. Review summary of reproductive and developmental toxicity study of KW-6485 (topiramate) study of administration during the period of fetal ontogenesis using rabbits. Data on file at RWJPRI (March 1994). 119 Zimmer EP, Williams ER, Cameron AM, et al. Twenty-four month oncogenicity study of topiramate administered as a dietary admixture to rats. Data on file at RWJPRI (October 1992). 120 Zona C, Barbaroise M, Kawasaki H, Avoli M. Effects induced by the anticonvulsant drug topiramate on voltage-gated sodium currents generated by cerebellar granule cells in tissue culture. Epilepsia 1996; 37(Suppl 5): 24. Citing Literature Volume4, Issue2June 1998Pages 165-186 ReferencesRelatedInformation" @default.
• W2091888711 created "2016-06-24" @default.
• W2091888711 creator A5015741749 @default.
• W2091888711 creator A5025475711 @default.
• W2091888711 creator A5032876422 @default.
• W2091888711 creator A5037856311 @default.
• W2091888711 creator A5081023621 @default.
• W2091888711 date "1998-06-01" @default.
• W2091888711 modified "2023-09-28" @default.
• W2091888711 title "The Preclinical and Therapeutic Activity of the Novel Anticonvulsant Topiramate" @default.
• W2091888711 cites W1967434979 @default.
• W2091888711 cites W1969545594 @default.
• W2091888711 cites W1975482049 @default.
• W2091888711 cites W1976354860 @default.
• W2091888711 cites W1986087375 @default.
• W2091888711 cites W1986166026 @default.
• W2091888711 cites W2004951945 @default.
• W2091888711 cites W2012891482 @default.
• W2091888711 cites W2027959147 @default.
• W2091888711 cites W2032090906 @default.
• W2091888711 cites W2033585926 @default.
• W2091888711 cites W2034474234 @default.
• W2091888711 cites W2040481962 @default.
• W2091888711 cites W2040597207 @default.
• W2091888711 cites W2043242122 @default.
• W2091888711 cites W2048986915 @default.
• W2091888711 cites W2049004435 @default.
• W2091888711 cites W2051430123 @default.
• W2091888711 cites W2057743042 @default.
• W2091888711 cites W2067849510 @default.
• W2091888711 cites W2072738567 @default.
• W2091888711 cites W2088276984 @default.
• W2091888711 cites W2102528887 @default.
• W2091888711 cites W2117449343 @default.
• W2091888711 cites W2120525553 @default.
• W2091888711 cites W2129745199 @default.
• W2091888711 cites W2135710730 @default.
• W2091888711 cites W2165630646 @default.
• W2091888711 cites W2171332093 @default.
• W2091888711 cites W4239833577 @default.
• W2091888711 cites W4253837878 @default.
• W2091888711 doi "https://doi.org/10.1111/j.1527-3458.1998.tb00062.x" @default.
• W2091888711 hasPublicationYear "1998" @default.
• W2091888711 type Work @default.
• W2091888711 sameAs 2091888711 @default.
• W2091888711 citedByCount "5" @default.
• W2091888711 countsByYear W20918887112012 @default.
• W2091888711 countsByYear W20918887112014 @default.
• W2091888711 countsByYear W20918887112017 @default.
• W2091888711 crossrefType "journal-article" @default.
• W2091888711 hasAuthorship W2091888711A5015741749 @default.
• W2091888711 hasAuthorship W2091888711A5025475711 @default.
• W2091888711 hasAuthorship W2091888711A5032876422 @default.
• W2091888711 hasAuthorship W2091888711A5037856311 @default.
• W2091888711 hasAuthorship W2091888711A5081023621 @default.
• W2091888711 hasConcept C15744967 @default.
• W2091888711 hasConcept C169760540 @default.
• W2091888711 hasConcept C2775858608 @default.
• W2091888711 hasConcept C2777683783 @default.
• W2091888711 hasConcept C2778186239 @default.
• W2091888711 hasConcept C71924100 @default.
• W2091888711 hasConcept C98274493 @default.
• W2091888711 hasConceptScore W2091888711C15744967 @default.
• W2091888711 hasConceptScore W2091888711C169760540 @default.
• W2091888711 hasConceptScore W2091888711C2775858608 @default.
• W2091888711 hasConceptScore W2091888711C2777683783 @default.
• W2091888711 hasConceptScore W2091888711C2778186239 @default.
• W2091888711 hasConceptScore W2091888711C71924100 @default.
• W2091888711 hasConceptScore W2091888711C98274493 @default.
• W2091888711 hasIssue "2" @default.
• W2091888711 hasLocation W20918887111 @default.
• W2091888711 hasOpenAccess W2091888711 @default.
• W2091888711 hasPrimaryLocation W20918887111 @default.
• W2091888711 hasRelatedWork W1968952460 @default.
• W2091888711 hasRelatedWork W1976737475 @default.
• W2091888711 hasRelatedWork W1987632177 @default.
• W2091888711 hasRelatedWork W1996956183 @default.
• W2091888711 hasRelatedWork W2005650300 @default.
• W2091888711 hasRelatedWork W2011248034 @default.
• W2091888711 hasRelatedWork W2024542241 @default.
• W2091888711 hasRelatedWork W2055130094 @default.
• W2091888711 hasRelatedWork W2062218729 @default.
• W2091888711 hasRelatedWork W2083568128 @default.
• W2091888711 hasRelatedWork W2318483329 @default.
• W2091888711 hasRelatedWork W2400925156 @default.
• W2091888711 hasRelatedWork W2403073194 @default.
• W2091888711 hasRelatedWork W2415311879 @default.
• W2091888711 hasRelatedWork W2415596871 @default.
• W2091888711 hasRelatedWork W2419611920 @default.
• W2091888711 hasRelatedWork W2430363796 @default.
• W2091888711 hasRelatedWork W2438625777 @default.
• W2091888711 hasRelatedWork W2465699952 @default.
• W2091888711 hasRelatedWork W2468325675 @default.
• W2091888711 hasVolume "4" @default.
• W2091888711 isParatext "false" @default.
• W2091888711 isRetracted "false" @default.
• W2091888711 magId "2091888711" @default.
• W2091888711 workType "article" @default.